Shanghai Junshi Biosciences' (SHA:688180, HKG:1877) net loss attributable to owners for 2025 narrowed year on year to 874.4 million yuan, or 0.87 yuan per share, according to a Hong Kong bourse disclosure on Saturday.
Both the pharmaceutical company's Hong Kong and Shanghai shares fell around 5% during Monday's afternoon trade.
The attributable loss a year earlier was 1.28 billion yuan, or 1.30 yuan per share.
Total operating income climbed 28% to 2.50 billion yuan from 1.95 billion yuan in the prior year.